TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Retention in Treatment on MAT for 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decrease in blood inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glycemic target goal achievement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in reticulocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusion requirement of PRBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood Inflammatory Marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Usability and acceptability of the self-management interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Enrollment of participants to the comparative self-management interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of times the participant records activities within the application
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: success rate of orthopedic management of the Z-foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Clinical Response at Test of Cure (TOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical recurrence of atrial fibrillation (AF) after catheter ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healthcare expenditure for one year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of clinical stable patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver apparent diffusion coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality indicators for STEMI care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathological Regression of Cervical Lesions to CIN 1 or Less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of grounding days from flying due to neck pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 3-month overall morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants With Photo-initiated Potential Sensitization Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of target diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of KRT-232
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional myocardial strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12 month cumulative pregnancy probability
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change of miR210 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in global cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall treatment success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients with detectable urine fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any Injection Risk (Monthly Versus Never)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Needle or Cooker Sharers (2 or More Versus None)
Endpoint domain: Adverse events/effects
Primary endpoint: Talked About HIV-related Topics With Drug Buddies (in the Past Month)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Time until initial request for postoperative analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Well-being in medical residents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cigarette Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confidence in Quit Attempt
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of pain at rest and on coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of maximum tobramycin concentration to minimal inhibitory concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local tolerability of IMD
Endpoint domain: Adverse events/effects
Primary endpoint: Change Over Time in the Anxiety Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change Over Time in Anhedonia Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects with PICC-associated thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent of subjects with PICC-associated thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Survival without a disabling stroke
Endpoint domain: Mortality/survival
Primary endpoint: Disabling stroke-free survival without device replacement or repair
Endpoint domain: Mortality/survival
Primary endpoint: Urinalysis-confirmed opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of event-free patients
Endpoint domain: Mortality/survival
Primary endpoint: Severity of autonomic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of sudomotor and vasomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in P.acnes colony count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: symptomatic bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Centered Outcome Measurement Mean Change After 6 Weeks (VAS, RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lumbar-spine Stiffness (LSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Flexion-Relaxation Ratio (FRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Malaria Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rifapentine exposure by median area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral synthesis rate of creatine phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebral brain glutamate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebral pH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of enrolled subjects with bacterial/viral infection
Endpoint domain: Adverse events/effects
Primary endpoint: knee functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness in diagnosing cause of AUB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Regression of Basal Cell Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Battelle Developmental Inventory (BDI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Early Coping Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Survey score on practicality of study algorithm
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treatment related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Planning Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form 12-item (SF-12) Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Heart rate response to rapid pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in left ventricular strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Limb Symmetry Index (LSI) of lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose based on tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose based on safety
Endpoint domain: Adverse events/effects
Primary endpoint: Patient comfort with immobilization techniques
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change Cervical Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of in-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Effect on HbA1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thiobarbituric acid reactive substances (TBARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Conjugated dienes (CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Catalase (CAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Superoxide dismutase (SOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glutathione peroxidase (GPx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Validated proficiency score (GAGES Global assessment for Gastrointestinal Endoscopy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Liver congestion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety assessment of ICC-1132 plus alhydrogel
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free-Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: symptom severity and functional outcome score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in State Trait Anxiety Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Generalized Anxiety Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression and Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity (SBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator-associated events
Endpoint domain: Adverse events/effects
Primary endpoint: Major Molecular Response Rate (MMR) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (complete and partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Emotional Visual Event Related Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Onset Diabetes post transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropraxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in WOMAC A (Pain) Dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of clinical failures
Endpoint domain: Mortality/survival
Primary endpoint: Confirmed CD4 count below 50/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: First or new AIDS-defining event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Illinois Agility Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walk and Turn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Custom Turns Course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Civilian Ambulatory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simulated Urban Combat Patrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Alive at One Year Post Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients Requiring Ventilator Support at One Year Post Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients receiving </= 5 mg/day prednisone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported device acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary excretion of Neutrophil gelatinase-associated lipocalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of PTS
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Left Ventricular End-diastolic Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedure Duration (Surgery Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean decrease in target lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Assessment using Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Assessment using Surgical Pain Scales (SPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of SST2 PET-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/tolerability (incidence of adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Motor Score in the OFF (UPDRS III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to complete tablet disintegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Events (MAEs) Within 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-12 of tegaprazan and metabolite M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of tegaprazan and metabolite M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-6 of metronidazole, tetracycline and bismuth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of metronidazole, tetracycline and bismuth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depth of keratinized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Height Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Extent of thermal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incidence rate of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to delirium onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of local and distant recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in patency of treated vein tracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Postoperative Pain Experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial Fibrillation Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Graft width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission (CDAI score of <150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with ovarian cyst or dermid cyst or endometrial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of cancer and other serious diseases
Endpoint domain: Mortality/survival
Primary endpoint: Change in alcohol's Tmax, Cmax, area under the curve and elimination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alcohol subjective effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Who Receive a Pap Test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sleep Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants Smoking Daily at 12th Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whether or Not Smoking Daily at 2 Years After High School
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma control rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiopulmonary exercise testing (CPET) endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borg modified 0-10 category ratio scale (Borg CR10) for breathlessness intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neck Disability Index (NDI) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Flexion Rotation Test (FRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee joint function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Serum Calcium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in acne lesions count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lowest oxygen saturation overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Immunogenicity-CD4+ T Cell Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity-modification of the Tumor Microenvironment (Part 2 Only)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change in student function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC: Area under the plasma-concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLr: Renal clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: pb drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diet adherence measured by ketones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diet adherence measured by 24-hour diet recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to End-of-study MBL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Successful Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infection rate of VEPTR Implants
Endpoint domain: Adverse events/effects
Primary endpoint: serum concentrations of fat soluble compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes